Dr. Adler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1055 Clermont St.
Rm. 8d126, Mirecc,Denver Vamc
Denver, CO 80220Phone+1 303-393-4645Fax+1 303-370-7519
Education & Training
University of ColoradoResidency, Psychiatry, 1976 - 1982
Rutgers Robert Wood Johnson Medical SchoolClass of 1976
Certifications & Licensure
CA State Medical License 1982 - 2025
CO State Medical License 1977 - 2025- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia Start of enrollment: 2005 Jan 01
- A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) Start of enrollment: 2011 Feb 01
Publications & Presentations
PubMed
- 95 citationsOlanzapine Reduces Craving for Alcohol: A DRD4 VNTR Polymorphism by Pharmacotherapy InteractionKent E. Hutchison, Angela Wooden, Robert M. Swift, Andrew Smolen, John E. McGeary
Neuropsychopharmacology. 2003-10-01 - 532 citationsNormalization of Auditory Physiology by Cigarette Smoking in Schizophrenic PatientsLawrence E. Adler, Lee D. Hoffer, Anne Wiser, Robert Freedman
The American Journal of Psychiatry. 1993-12-01 - 219 citationsSmoking and mental illness.Sherry Leonard, Lawrence E. Adler, Khalid Benhammou, Ralph Berger, Charles R. Breese
Pharmacology, Biochemistry, and Behavior. 2001-12-01
Grant Support
- Atypical Antipsychotics And P50 Sensory GatingNational Institute Of Mental Health2004–2008
- Atypical Antipsychotics And P50 Gating In SchizophreniaNational Institute Of Mental Health1999–2001
- Atypical Antipsychotics And P50 Gating In SchizophreniaNational Institute Of Mental Health1998–2000
- Nicotine On Sensory Gating Of Auditory Evoked Potentials In ManNational Center For Research Resources1991–1999
- Cholinergics And Sensory Gating In SchizophreniaNational Institute Of Mental Health1994–1997
- Cholinergic Mechanisms Of Sensory Gating--SchizophreniaNational Institute Of Mental Health1994–1997
- Methylphenidate PLUS Cholinergic Mediation Of P50 Auditory Sensory GatingNational Center For Research Resources1995
- Bromocriptine And Sensory GatingNational Center For Research Resources1993–1995
- Cholinergic Mediation Of P50 Auditory Sensory GatingNational Center For Research Resources1994
- Cholinergic Mechanisms Of Sensory Gating In Schizo.National Institute Of Mental Health1993
- Catecholaminergic Drugs On Sensory Gating Of Auditory Evoked PotentialsNational Center For Research Resources1989–1992
- Catecholamines And Sensory Gating In SchizophreniaNational Institute Of Mental Health1988–1992
- Dextroamphetamine On Sensory Gating In Auditory Evoked PotentialsNational Center For Research Resources1989–1991
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
